Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2017

Study Completion Date

May 31, 2018

Conditions
Heart FailurePulmonary Hypertension
Interventions
DRUG

Tadalafil

Tadalafil tablets, 20 mg to 40 mg per day x 48 weeks

DRUG

Placebo

Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Carelon Research

OTHER

lead

Massachusetts General Hospital

OTHER

NCT01960153 - Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage | Biotech Hunter | Biotech Hunter